 AIkido Pharma Inc. Nasdaq: AIKI AIkido or the Company today announced that on April 13, 2020, the Company executed a Master License Agreement the License Agreement with the University of Maryland, Baltimore UMB. The License Agreement covers specific antiviral compounds discovered by UMB. The compounds seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV, Ebolavirus and Marburg virus. 